837
Participants
Start Date
November 26, 2014
Primary Completion Date
September 29, 2015
Study Completion Date
June 17, 2020
Guselkumab 100 mg
100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
Placebo for guselkumab
Subcutaneous injections to maintain the blind.
Adalimumab
80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
Placebo for adalimumab
Subcutaneous injections to maintain the blind.
Los Angeles
San Diego
San Francisco
Aurora
Farmington
Clearwater
Coral Gables
Ocala
Alpharetta
Rolling Meadows
Plainfield
Boston
Troy
New Brighton
St Louis
East Windsor
Albuquerque
Portland
Pittsburgh
Johnston
Arlington
Austin
Dallas
San Antonio
Webster
Norfolk
Darlinghurst
East Melbourne
Hectorville
Liverpool
Melbourne
Westmead
Woden
Woolloongabba
Calgary
Edmonton
Vancouver
St. John's
Halifax
Ajax
London
North Bay
Peterborough
Montreal
Berlin
Bonn
Dresden
Essen
Frankfurt am Main
Gera
Hamburg
Kiel
Lübeck
Mahlow
Münster
Tübingen
Budapest
Debrecen
Kaposvár
Kecskemét
Pécs
Szeged
Bialystok
Bydgoszcz
Lodz
Olsztyn
Warsaw
Wroclaw
Kirov
Krasnodar
Lipetsk
Moscow
Rostov-on-Don
Ryazan
Saint Petersburg
Stavropol
Ulyanovsk
Yekaterinburg
Bundang
Busan
Daejeon
Seoul
Suwon
Barakaldo
Barcelona
Córdoba
Madrid
Manises
Palma de Mallorca
Salamanca
San Sebastián de los Reyes
Valencia
Kaohsiung City
Taichung
Tainan City
Taipei
Taoyuan District
Janssen Research & Development, LLC
INDUSTRY